

# Development of the novel HER2 TKI YH42946 for Solid Tumors



ONCOLOGY	Phase 1
Product Type	Small molecules
Indication	Locally Advanced or Metastatic Solid Tumors with Oncogenic HER2 aberrations, EGFR Mutation (Ex20ins)
Target	HER2 aberrations, EGFR Mutation (Ex20ins)
MoA(Mechanism of Action)	YH42946 is an orally available small molecule drug that potently inhibits oncogenic HER2 aberrations
Competitiveness	<ul style="list-style-type: none"> <li>• Providing an oral targeted treatment option that is mechanistically distinct from antibody-drug conjugate drug which is currently only approved drug for HER2-mutated NSCLC</li> <li>• Potential for development in combination with other HER2-targeted therapies or standard treatment to boost clinical efficacy</li> <li>• Potential to expand indication to other solid tumors with HER2 mutation or solid tumors with HER2 overexpression/amplification based on a broad spectrum of inhibitory activities.</li> </ul>
Development Stage	Phase 1
Route of Administration	Oral Administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*